“Pharmacogenetics of siponimod: A systematic review” by Díaz-Villamarín et al. – Information is power

Abstract

On August 12, 2022, Biomedicine and Pharmacotherpy published a systematic review on the pharmacogenetics of siponimod by Díaz-Villamarín et al. [1] We would like to acknowledge the work done by the authors, as siponimod is a drug that may occupy a priority place in the management of secondarily progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity. Therefore, we believe that research aimed at clarifying the impact of genetic variants on the effectiveness and safety of this drug is needed; therefore, we applaud the authors’ efforts with this systematic review. We consider that there are several inconsistencies in the therapeutic recommendations contained in the siponimod drug label and in those issued by the two most relevant international associations in pharmacogenetics: the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG).